Harmony Biosciences Holdings, Inc. (HRMY)

Market Cap	1.56B
Revenue (ttm)	772.53M
Net Income (ttm)	180.90M
Shares Out	57.53M
EPS (ttm)	3.10
PE Ratio	8.74
Forward PE	8.08
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,133,711
Open	26.58
Previous Close	26.59
Day's Range	26.58 - 27.34
52-Week Range	26.26 - 41.61
Beta	0.79
Analysts	Strong Buy
Price Target	51.30 (+89.65%)
Earnings Date	Oct 28, 2025

About HRMY

Harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare and other neurological diseases in the United States. The company offers WAKIX (pitolisant), a molecule with a novel mechanism of action for the treatment of excessive daytime sleepiness in adult patients with narcolepsy. It also develops Pitolisant that is in Phase 3 clinical trial for the treatment of Prader-Willi Syndrome (PWS); in Phase 2 clinical trial to treat Myotonic Dystrophy (DM1); a...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Aug 19, 2020
• Employees: 268
• Stock Exchange: NASDAQ
• Ticker Symbol: HRMY
• Website: https://www.harmonybiosciences.com

Financial Performance

In 2024, HRMY's revenue was $714.73 million, an increase of 22.80% compared to the previous year's $582.02 million. Earnings were $145.49 million, an increase of 12.91%.

Analyst Summary

According to 10 analysts, the average rating for HRMY stock is "Strong Buy." The 12-month stock price target is $51.3, which is an increase of 89.65% from the latest price.

Price Target

$51.3

(89.65% upside)

Analyst Consensus: Strong Buy